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1.
CONTROLLING CALCUM COMPOUND
FORMATION IN BOCOMPATIBLE
MATERALS FOR TISSUE REGENERATION
AND REPAIR IN MAMMALS
REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part application of
PCT/US2010/048778 published as WO 2011/084.192 and
filed on Sep. 14, 2010, claiming priority to U.S. application

10

Ser. No. 12/683,280 filed Jan. 6, 2010, the entire disclosures

of which are incorporated herein by reference.
STATEMENT OF GOVERNMENT INTEREST
15

This invention was made with Government support under
Department of the Army contract W81XWH-08-1-7065.
The Government may have certain rights in the invention.
FIELD OF THE INVENTION

This invention relates to biocompatible compositions for
Surface and Subsurface implantation into mammals to facili
tate tissue repair, regeneration, and proliferation.
25

BACKGROUND OF THE INVENTION

Bioactive glasses have been known for nearly 40 years
and are considered osteoinductive and osteoconductive.

They are currently used in a variety of bone repair and
regeneration applications since these glasses react in a
favorable way with the bodily fluids to form a calcium
phosphate compound known as hydroxyapatite (HA) or
carbonated hydroxyapatite (HCA). Since HA or HCA is the
mineral component of natural bone, bioactive glasses form
a strong chemical bond to human bone and over a period of
time they are considered to be remodeled by the body to

30

35

form new bone.

Silicate-based glasses have been used as a basis for
implantable compositions to Support the bonding, growth or
genesis of bone by fostering a Supportive environment
between the material and living, bone progenitor cells. It is
widely recognized that Successful bioactive glasses include
calcium and silica in order to foster the needed Supportive
environment. Certain of these compositions are considered
bioactive since they possess Surfaces capable of fostering a
calcium phosphate layer which, in turn, promotes bone
bonding to the material. For example, U.S. Pat. No. 5,204.
106 discloses a composition termed 45S5 glass which is
composed of NaO CaO POs SiO.
Day et al. U.S. Pat. No. 6,709,744 describes biocompat
ible materials for implantation which include borate-based
glass or ceramic materials containing Na2O, CaO, P.O.s, and
BO. A specific example is a glass containing about 22.9 wt
% NaO, about 22.9 wt % CaO, about 5.6 wt % POs, and
about 48.6 wt % B.O. These materials contain a high CaO
concentration to facilitate the formation of hydroxyapatite
when exposed to phosphorus-containing fluids in vivo or
prior to implantation.
There is a continuing need for a wider variety of biocom
patible materials which promote rapid repair of mammalian

40

45

50

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A shows chopped fibers 2 to 3 mm in length, 100
to 300 um in diameter, used for making compositions of the
55

invention.
FIG. 1B shows a ceramic mold used to hold the fibers

during the heat treatment.
FIG. 1C is an example of a scaffold that weighs 70 mg and
has dimensions of 7 mm in diameter and 2 mm thick.
60

tissue.
SUMMARY OF THE INVENTION
65

Briefly, therefore, the invention is directed to the repair
and regeneration of both soft and hard tissue (bones) in a

2
time frame which is more rapid than is currently possible
with bioactive silicate glasses and wherein the bioactive
glasses react with the bodily fluids to form not only hydroxy
apatite but also other calcium containing compounds which
are biologically more preferred than the hydroxyapatite
reaction product formed by the reaction of silicate glasses,
and in certain applications to form Such other calcium
containing compounds and affirmatively avoid forming
hydroxyapatite.
In another aspect, the invention is directed to a biocom
patible composition for tissue repair or regeneration in
mammals comprising one or more glass former compounds
selected from the group consisting of BOs, POs, and SiO,
director elements selected from the group consisting of Cu,
Sr., Zn, Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg,
Si and/or Ni to promote in vivo calcium compound forma
tion of calcium carbonate or other calcium compounds other
than hydroxyapatite or amorphous calcium-containing mate
rials other than hydroxyapatite; wherein upon direct appli
cation of the biocompatible composition to a mammalian
host, calcium carbonate or other calcium compounds other
than hydroxyapatite or amorphous calcium-containing mate
rials other than hydroxyapatite form upon bioreaction of the
composition with bodily fluids.
The invention is also directed to use of a composition
comprising one or more glass former compounds selected
from the group consisting of BOs, P.O.s, and SiO, and
director elements selected from the group consisting of Cu,
Sr., Zn, Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg,
Si and/or Ni to promote in vivo calcium compound forma
tion of calcium carbonate or other calcium compounds other
than hydroxyapatite or amorphous calcium-containing mate
rials other than hydroxyapatite.
In another aspect, the invention is directed to a method for
forming a calcium compound in vivo in a mammal com
prising implanting into the mammal a composition compris
ing one or more glass former compounds selected from the
group consisting of BO, P.O.s, and SiO, and director
elements selected from the group consisting of Cu, Sr., Zn,
Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, Si and/or
Ni to promote in Vivo calcium compound formation of
calcium carbonate or other calcium compounds other than
hydroxyapatite or amorphous calcium-containing materials
other than hydroxyapatite.
Other objects and features of the invention are in part
apparent and in part pointed out hereinafter.

Scaffold porosity is 50+2%.
FIG. 2 is a schematic showing Subcutaneous scaffold
implant sites located on the back of a rat.
FIG. 3 shows glass scaffolds according to the invention
after six weeks implantation, except for the 13-93B3 scaf
fold which was implanted for four weeks.
FIG. 4 shows XRD patterns for randomly oriented scaf
folds according to the invention after implantation. The
respective lines have been displaced vertically for clarity.

US 9,561,303 B2
4
hydroxyapatite materials. In accordance with this invention,
the type of calcium-containing materials which forms when
a bioactive glass reacts in vivo is controlled and directed, so
that in some embodiments calcium-containing materials are

3
FIG. 5 is an SEMBSE image of a cross sectioned Cu-3
fiber scaffold that was implanted in the subcutaneous tissue
of a rat for six weeks.

FIG. 6 is an SEMBSE image of a cross sectioned CS fiber
scaffold implanted subcutaneously in the back of a rat for six

formed in addition to HA, and in other embodiments cal

weeks.

FIG. 7 is an SEMBSE image of a CS fiber implanted
subcutaneously in the back of a rat for six weeks.
FIG. 8 is an SEMBSE image of a cross sectioned CSZ
fiber scaffold implanted subcutaneously in the back of a rat

10

for six weeks.

FIG. 9 is an SEMBSE image of a cross sectioned CSZ
fiber scaffold implanted subcutaneously in the back of a rat
for six weeks.

FIG. 10 is an SEMBSE image of a cross sectioned CSZF
fiber scaffold that was implanted subcutaneously in the back

15

of a rat for six weeks.

FIG. 11 is an EDS phase map of CSZF reacted fiber after
six weeks in rat subcutaneous tissue. The SEMBSE image is
shown bottom right of the image for reference.
FIG. 12 is an SEMBSE image of a CSZF fiber implanted
subcutaneously in the back of a rat for six weeks.
FIG. 13 is a higher magnification photograph of the image
in FIG. 12.

FIGS. 14 and 15 are XRF patterns of compositions of the
invention as-made and after implantation in vivo.
FIG. 16 is an XRD pattern of a composition of the
invention after one and two weeks in simulated bodily fluids.
FIGS. 17-23 are micro Raman spectra of compositions of
the invention as described in Example 7.
FIG. 24 is a schematic presentation of how hydroxyapa
tite formation is inhibited by the presence of six coordinated
ions in aqueous environments.

25

DESCRIPTION OF PREFERRED
EMBODIMENTS

35

The compositions of the invention employ one, two, or all
three of BOs, SiO, or POs as glass former compounds.
The compositions contain calcium and one or more elements
which direct the formation of calcium-containing com
pounds other than hydroxyapatite upon biodegradation of
the compositions in vivo. The compositions are in the form
of particulates, scaffold, mesh, or other form which is
implantable or a form such as mesh or wrap which can be
applied to the skin. The below discussion focuses on implan
tation of the composition into a mammalian host; but in all
significant aspects the invention is equally Suitable for other
forms of direct application to the mammalian host such as a
mesh or wrap applied over the skin. In other words, the
invention is applicable to both Surface and Subsurface appli
cation, provided the composition is exposed to the mamma
lian hosts bodily fluids.
All known bioactive glasses such as the well known 45S5
and 13-93 react with the bodily fluids to form a hydroxy
apatite type material. The term “bioactive' has come to refer
specifically to materials which react with bodily fluids to
form a calcium phosphate material Such as hydroxyapatite,
non-stoichiometric hydroxyapatite, amorphous hydroxyapa
tite, or carbonated hydroxyapatite. As used herein, the term
“hydroxyapatite” designates these materials collectively

30

40

45

TABLE 1.
50

Material

Hydroxyapatite (HA)
Calcite
Waterite
55 Calcium Fluoride

Tricalcium Phosphate (TCP)
Octacalcium Phosphate (OCP)
Monetite (DCPA)
Brushite (DCPD)
Calcium Hydroxide

60

unless stated otherwise. And while these are desirable mate

rials for many in vivo applications because, for example, HA
mimics bone, there are applications where it is desirable to
form other types of calcium-containing materials when a
bioactive glass reacts with bodily fluids. And there are
applications where it is desirable to avoid the formation of

cium-containing materials are formed instead of HA. This
discovery offers the possibility of expanding the uses of
bioactive glasses for bone replacement/repair applications
and creating bioactive glasses which can react faster in the
body and can convert to new bone more quickly than the
presently available bioactive glasses. To distinguish from
“bioactive' and “bioactivity” which have come to refer to
HA formation, this application uses the terms “bioreactive'
and “bioreactivity” to refer to reaction of the glass materials
to form calcium-containing compounds which are not
hydroxyapatite.
A material that reacts with the bodily fluids to form calcite
is resorbed by the body faster than a material that reacts to
form hydroxyapatite (HA), especially stoichiometric crys
talline HA. The solubility of hydroxyapatite is 5 mg/L at pH
7.3, whereas the solubility of calcite is 6.6 mg/L. Calcite has
also been found to be osteogenic (promotes bone growth),
and when compared to hydroxyapatite is more effective in
promoting bone growth. Therefore, a glass that forms cal
cium carbonate, especially in the form of calcite—the most
stable polymorph of calcium carbonate CaCO is expected
to be resorbed faster by the body than a glass that forms
hydroxyapatite (Caio (PO4)(OH)2). Because calcium car
bonate is also osteogenic in that it promotes new bone
formation, it promotes faster complete healing of bony
defects. Calcium compounds other than hydroxyapatite
include, for example, calcite, Vaterite (CaCO), calcium
fluoride (CaF) tricalcium phosphate (TCP)(Ca(PO), tet
racalcium phosphate (Ca(PO4)2O), oxyapatite, octacalcium
phosphate (OCP)(Cash (PO)-5H2O, monetite (DCPA)(CaHPO), brushite (DCPD)(CaHPO-2HO), and calcium
hydroxide (Ca(OH). In some instances intermediate prod
ucts which one might consider to not be compounds per se
will form; so in this respect the invention involves forming
calcium-containing materials (i.e., not necessarily com
pounds), which are not hydroxyapatite. In a particular sys
tem. Some of these may be metastable and transition com
pounds. From solubility data for many of these compounds,
one would be expected hydroxyapatite to precipitate early,
because of its low solubility, relative to these other com
pounds, upon introduction of Ca into a system containing P.
O. H. and C, such as bodily fluids:

65

Chemical Formula

Solubility (mg/L)

Cao(PO4)6(OH)2

5*

CaCO
CaCO
CaF,

Ca(PO)
Cash (PO) 5H2O
CaHPO,
CaHPO 2H2O
Ca(OH)2

6.6
11
16

33:
39:
135*
1948
1600

1Hydroxyapatite and Related Materials, Brown and Constantz, 1994
2Handbook of Chemistry and Physics (90th edition) 2009-2010
*Denotes a value calculated from solubility isotherms from FIG. 1 on page 74, pH = 7.3

So if a source of calcium such as a Ca-containing biode
gradable glass is implanted into an environment of P. O. and
C, one would expect, as the Ca ions are released, to form
hydroxyapatite sooner than calcite. However, if HA can be

US 9,561,303 B2
5
prevented from forming then the next least soluble phase,
calcite, would be expected to form. One would also expect
these other compounds, if present in a particular system Such
as bodily fluids, would dissociate into Ca, P etc. ions
relatively sooner than hydroxyapatite. Furthermore, if cal
cite dissociates into its ions sooner than does hydroxyapa
tite, then such ions are available to perform a desired
function in the body sooner. That function in the instance of
bone repair is to grow hydroxyapatite at damaged bone sites.
In other words, calcite facilitates growth of remodeled
hydroxyapatite on a bone Substrate more quickly than
hydroxyapatite does. It may therefore be advantageous for a
bone repair implant to, upon implantation, form calcite
instead of or in addition to hydroxyapatite. This invention
leverages this concept by including director elements which
essentially alter the normal hierarchy of calcium compound
formation one would expect from the above solubility data
as well as from the accepted maxim in the field that
calcium-containing glasses in physiological fluids form
hydroxyapatite. That is, the glass compositions of this
invention are specifically formulated to biodegrade in physi
ological fluids to form calcite and/or other calcium-contain
ing compounds instead of, or in addition to, hydroxyapatite.

6
In accordance with this invention, the glass composition is
formulated to include the one or more director elements so

10

calcite formation reaction is as follows:
15

25

tions in vivo constitute minor amounts of Cu, Sr., Zn, Fe, Mn,
30

compound formation toward calcium carbonate or other
calcium compounds other than hydroxyapatite or amor
phous calcium-containing materials other than hydroxyapa
tite. In one embodiment, the director element is Cu, Zn, Fe,

Mn, Ba, Co, S. V. and/or Y either individually or in com
bination; and in one preferred embodiment, the director

35

element is Cu, Zn, Fe, Mn, Ba, Co, and/or S. Such as in one

more particularly preferred embodiment where the director

in accordance with this invention. These elements have
40

one director element or two or more of the director elements.

The invention in one aspect therefore involves use of a
composition to promote in Vivo calcium formation of cal
cium carbonate or other calcium compounds other than
hydroxyapatite or amorphous calcium-containing materials
other than hydroxyapatite, wherein the composition com
prises one or more glass former compounds selected from
the group consisting of BO, P.O.s, and SiO, and director
elements selected from the group consisting of Cu, Sr., Zn,
Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, Si and/or
Ni. As is evident from the following description, the inven
tion includes a method for forming a calcium compound in
Vivo in a mammal comprising implanting into the mammal
a composition comprising one or more glass former com
pounds selected from the group consisting of BO, P.O.s,
and SiO, and director elements selected from the group
consisting of Cu, Sr., Zn, Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co.
S, Al, Ti, Y. Mg, Si and/or Ni to promote in vivo calcium
compound formation of calcium carbonate or other calcium
compounds or amorphous calcium-containing materials
other than hydroxyapatite.
Calcium-containing implantable bioactive glasses form
hydroxyapatite upon reaction with bodily fluids according to
the following ideal reaction:

ment is incorporated into, for example, a scaffold of a
biocompatible composition which is implantable at a mam
mal’s Surface or Subsurface. The scaffold composition may
optionally provide ions for biological use by the mammal, as
described in co-pending application Ser. No. 12/683,280, the
entire disclosure of which is incorporated by reference. The
elements which function as director elements may also have
other benefits, or separate trace elements may be incorpo
rated as described in the co-pending application, indepen
dent of the elements’ ability to function as director elements
beneficial effects such as an effect on endothelial cell migra

element is Zn and/or Fe, or one or more of Cu, Mn, Ba, Co,

and/or S. Wherever this description refers to “director ele
ment in the singular, it is to be understood to encompass

particular, it is believed that an element with a relatively
Smaller ionic radius Such as less than about 1 angstrom, or
on the order of 0.8 angstroms or less, provides moderate to
severe inhibition of hydroxyapatite formation, and biases the
system toward calcite formation.
The invention is useful in a wide variety of implantable
applications and other tissue regenerative applications.
Herein it will be described in the context of an implantable
scaffold. In accordance with this invention, a director ele

Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, Si and/or Ni
which are employed as a so-called “director elements’ to
control the formation of HA and bias the in vivo calcium

Without being bound to a particular theory, it appears the
atomic/ionic radius of a particular element has an impact on
its efficacy as a director element alone or in combination
with other elements in accordance with this invention. In

In accordance with this invention, the elements which

direct the formation of calcium-containing compounds other
than hydroxyapatite upon biodegradation of the composi

as to produce desired calcium compounds or amorphous
calcium-containing materials other than hydroxyapatite. In
Some embodiments, these other calcium compounds and/or
materials are formed entirely instead of hydroxyapatite. In
other embodiments, a mixture of hydroxyapatite and one or
more other calcium-based compounds is formed. In one
preferred embodiment of the invention, the implantable
glass composition is formulated to promote the formation of
calcite upon reaction with bodily fluids in vivo. The major
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tion which can be useful for blood vessel formation and have

importance for tissue regeneration. In this way, these ele
ments promote angiogenesis, which is a critical function in
promoting tissue growth, such as in wound healing. This is
in distinction from promoting osteoconductivity, which
refers to providing bone growth factors to a site to promote
bone growth. Angiogenesis, which involves increasing vas
cularity, i.e., vessel growth, is distinct from osteoconductiv
ity. However, certain of these director elements assist in
promoting osteoconductivity as well.
The scaffold of the invention comprises a scaffold body
comprising a biocompatible material in the form of one or
more of fibers, hollow fibers, tubes, ribbons, solid spheres,
hollow spheres, particles, bonded particles, and combina
tions thereof. In many of the more preferred embodiments,
the form is loose or bonded fibers, or bonded particles.
Generally speaking, a scaffold composed of multiple fibers
and/or other of these elements has a weight of at least about
10 milligrams, such as between about 10 milligrams and
about 500 grams, for example between about 20 milligrams
and about 2500 milligrams. The scaffold weight/dimensions
depend upon the size of the wound/space being treated. The
biocompatible material is borate-based, phosphate-based,
and/or silicate-based and is glass, crystalline, or a combi
nation of glass and crystalline.
The biocompatible material fibers, spheres, or other
shaped components in Some embodiments are in a loose
assembly of nonbonded components. Alternatively, they are

US 9,561,303 B2
7
bonded to each other, typically by heating, to define a
scaffold body and provide a scaffold body compressive
strength adequate for the particular application, for example
of greater than 0.4 MPa for some applications. The desired
compressive strength is selected so that the components are
in no sense free flowing, and so that the scaffold body can
be handled without disintegrating into the individual body
components. The desired compressive strength is also
selected to provide the strength that is required to remain
integral after implantation, whether for repair of a load
bearing body part or non-load-bearing part, or one Subject to
impact or significant movement. In some preferred embodi
ments, the compressive strength of the scaffold body is at
least about 5 MPa, while in other embodiments where

greater rigidity is required, the compressive strength is at

8
concentration between about 0.05 and 10 wt % by virtue of
the materials Cu content, regardless of its undualifying Sr
COntent.

Where Cu is desired as the director element, the source of

Cu to the glass or crystalline biocompatible material may be
a copper oxide Such as CuO or CuO or other copper
compounds such as copper nitrate or copper Sulfate, for
example. In one embodiment, Cu is incorporated into the
glass in a CuO concentration of at least about 0.05 wt %, or
10

about 0.05 and about 5 wt %, for example between about 0.1
and about 2.5 wt %

Where Sr is desired as the director element, the source of

15

least about 20 MPa, such as between about 20 and about 200
MPa.

The initial surface area of the scaffold varies widely
depending on the scaffold morphology—for example,
whether it is all fibers, the fiber dimensions, the particle size,
etc. Moreover, the Surface area changes during biodegrada
tion. Generally speaking, scaffolds of the fibrous morphol
ogy have a surface area/bulk scaffold volume of between

about 50 and about 1000 cm, such as between about 50
and about 500 cm. One exemplary scaffold has a surface
area/unit bulk volume of 134 cm', based on its dimensions

about 0.05 and about 5 wt %, for example between about 0.1
and about 2.5 wt %

Where Zn is desired as the director element, the source of

25
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One or more director element compounds are incorpo
rated into the implantable material in a concentration of at

least about 0.05 wt %, or at least about 0.1 wt %. In most
instances, the concentration is less than 10 wt %, or less than
5 wt %, such as between about 0.05 and about 5 wt %, for

example between about 0.1 and about 2.5 wt % (per com
pound). A director element compound is an oxide or other
compound of one of the director elements Cu, Sr., Zn, Fe,
Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, Si and/or
Ni, for example CuO, SrO, ZnO, or FeO. For example, Zn
may be an oxide, carbonate, nitrate or other. While the

Sr to the glass or crystalline biocompatible material may be
an oxide such as SrO or other Sr compounds such as SrCO,
for example. In one embodiment, Sr is incorporated into the
glass in a SrO concentration of at least about 0.05 wt %, or
at least about 0.1 wt %. In most instances, the concentration
is less than 10 wt %, or less than 5 wt %, such as between

of being a cylinder 7 mm in diameter and 2 mm high. The

surface area of the starting glass fibers was 10.27 cm and
the bulk volume of the cylinder was 7.7x10, cm.

at least about 0.1 wt %. In most instances, the concentration
is less than 10 wt %, or less than 5 wt %, such as between

35

Zn to the glass or crystalline biocompatible material may be
an oxide Such as ZnO or other Zn compounds such as
Zn(PO4)-XH2O, for example. In one embodiment, Zn is
incorporated into the glass in a ZnO concentration of at least

about 0.05 wt %, or at least about 0.1 wt %. In most
instances, the concentration is less than 10 wt %, or less than
5 wt %, such as between about 0.05 and about 5 wt %, for

example between about 0.1 and about 2.5 wt %
Where Fe is desired as the director element, the source of
Fe to the glass or crystalline biocompatible material may be
an oxide Such as FeC), Fe-O, Fe2O, or other Fe compounds
such as FeSO-7HO, for example. In one embodiment, Fe
is incorporated into the glass in a Fe2O concentration of at
least about 0.05 wt %, or at least about 0.1 wt %. In most
instances, the concentration is less than 10 wt %, or less than
5 wt %, such as between about 0.05 and about 5 wt %, for

40

example between about 0.1 and about 2.5 wt %.
Calcium is incorporated into the compositions of the

director elements are described here and in the claims as

invention to facilitate the formation of calcium carbonate

director element compounds and described as various oxides
by weight %, those skilled in the art understand that in the
final glass or glass/crystalline composition, the oxide com
pounds are dissociated, and the specific oxides, e.g., CuO.
SrO, ZnO, or FeO are not separately identifiable or even
necessarily separately present. Nonetheless, it is conven
tional in the art to refer to the final composition as containing
a given "% of the individual oxides, so that is done here. So
from this perspective, the oxides herein are on an equivalent

(such as calcite) and optionally other calcium-containing
compounds upon bioreaction of the composition with bodily
fluids after implantation into a mammalian host. The CaO
concentration of the composition is between about 2.5 and
about 50 wt %, for example between about 5 and about 40
wt %. In a preferred embodiment, the CaO concentration is
between about 12 and about 25 wt.%. In the composition, the
oxide compounds are dissociated, and the specific CaO or
other oxides are not typically not separately identifiable or
even necessarily separately present. Nonetheless, it is con
ventional in the art to refer to the final composition as
containing a given 9% of the individual oxides, so that is done
here. This CaO concentration is typically provided in the
form of a Ca compound such as CaO or CaCO, Ca(NO),
Ca(OH) and others.
The director element and biocompatible composition are
carefully selected and formulated to provide a specifically
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basis.

Where the implantable biocompatible material is borate
based or phosphate-based, the director element concentra
tion is less than 5 wt %, and it may be higher and up to 10
wt % where the biocompatible material is silicate-based.
More than one of these director elements can be employed
in a single composition. Also, certain of these elements may
be present in greater amounts in that they are not being used
as director elements in accordance with this invention. For

55

60

example, a composition made of a biocompatible glass
material which contains 0.4 wt % CuO and 15 wt % SrO
contains Cu as a director element in accordance with this

invention; and it contains Sr, but not as a director element in
accordance with this invention. Such a material would

indeed satisfy the requirement herein for a director element
from the group Cu, F, Fe, Mn, Mo, Ni, Sr. and Zn in a
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timed release of director element based on flow of blood or

other physiological fluids through the scaffold as the bio
compatible composition biodegrades in the mammalian
host. The director element is an integral component of the
biocompatible composition and is chemically dissolved in
the material. This is in sharp contrast to being in the form of
a coating on the glass or being simply adsorbed onto the
material as, for example, adsorbed onto a water insoluble
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implantable compound. Since the director element is chemi
cally dissolved in the glass material, it is released into the
host mammal incrementally as the glass biodegrades, and
over that same period during which the glass biodegrades. In
contrast, a coating or adsorbed material is released more
quickly, and its release cannot be controlled by controlling
the composition of the overall glass material. In one embodi
ment, the director element is generally macro-homoge
neously present in the biocompatible composition to facili
tate release over the entire degradation life of the
composition. As blood and or other fluids flow through the
scaffold and the scaffold biodegrades in the host mammal,
the director element is released to provide its advantageous
angiogenic effect over time in promoting benefits to the host
in the area of the implantation. So, for example, as the
borate-based, phosphate-based, or silicate-based composi
tion biodegrades, it releases director element to promote
angiogenesis or some other desirable biological function.
The glass formers in certain embodiments of the invention
are concentration balanced to impart the desired biodegrad
ability. For example, in the B3-CSZ composition of below
Example 1, the concentrations of the glass formers borate,
silicate, and phosphate are balanced to 51.2 wt %, 0 wt %,
and 3.86 wt %, respectively, and in the CSZF composition
to 50.88 wt %, 0 wt %, and 3.84 wt %, respectively, with
respect to themselves and with respect to the other compo
nents in the material NaO, CaO, and KO. Balancing in this
regard encompasses balancing the concentration of one glass
former with other components, such as with those glasses
contain borate and other components, but no phosphate or

10
director element concentration is released within six weeks;
and in at least 68% of rats at least 15 wt % of the scaffolds

director element concentration is released; and in at least
90% of rats at least 10 wt % of the scaffolds director
element concentration is released.

On the other hand, the scaffold does not biodegrade so
quickly that it does not provide its healing benefits for
sufficient time. For example, at least 50 wt % of the scaffold
10

15

two weeks; and in at least 90% of rats at least 25 wt % of

the scaffold does not biodegrade within two weeks.
25

but can also manifest itself as another reaction of the scaffold

two weeks. That is, the concentrations of glass formers are
balanced such that at least about 50 wt % of the director
30

35

remains for at least two weeks; and in at least 68% of rats
at least 37.5 wt % of the scaffolds director element con
40

centration remains for at least two weeks; and in at least 90%
of rats at least 25 wt % of the scaffolds director element
concentration remains for at least two weeks.

45
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release of director element.

Similarly, in another aspect, the concentrations of glass
55

from the scaffold within six weeks of implantation in its
mammalian host. For example, the concentrations of glass

As noted above, the biocompatible materials, whether in
the form of scaffolds or other shapes, biodegrade in physi
ological fluids. However, in comparison to articles charac
terized as “water soluble' which dissolve relatively rapidly
(over a period of, e.g., three weeks or less) in aqueous
solutions, the biocompatible materials of the invention are
not water soluble, that is, they are resistant to rapid water
solubility. For example, scaffolds made from them having a
Surface area and size of practical application for use as an
implantable scaffold do not completely dissolve in a less
than several weeks (e.g., six weeks) at 37°C. in an aqueous
phosphate solution or an aqueous Solution with a miscible
Solvent Such as methanol, ethanol, isopropanol, acetone,
ethers or the like. As understood in the art, materials which

formers are balanced such that at least about 20 wt % of the
director element concentration in the scaffold is released

from the scaffold into the host within six weeks of implan
tation in a Fisher 344 rat having an age between 9 and 11
weeks and a weight between 200 and 300 grams. In accord
with this measure, the testing is performed on rats with a
standard deviation of 25% (relative) of the biocompatible
material and a population size of 10. In other words, when
10 of these scaffolds are implanted into the subcutaneous
sites of rats, on average at least 20 wt % of the scaffolds

element remains for at least two weeks after implantation in
a Fisher 344 rat having an age between 9 and 11 weeks and
a weight between 200 and 300 grams. In accord with this
measure, the testing is performed on rats with a standard
deviation of 25% (relative) of the biocompatible material
and a population size of 10. In other words, when 10 of these
scaffolds are implanted into the rats, on average at least 50
wt % of the scaffolds director element concentration

material involving a change of composition which results in
formers are balanced such that at least about 20 wt % of the
director element concentration in the scaffold is released

Moreover, in these embodiments, at least 50 wt % of the
scaffold director element concentration remains for at least

silicate.

In many preferred embodiments of the scaffold, the con
centrations of glass formers are balanced such that at least
about 20 wt % of the biocompatible material biodegrades
within six weeks of implantation in its mammalian host. For
example, the concentrations of glass formers are balanced
such that at least about 20 wt % of the biocompatible
material biodegrades within six weeks of implantation in a
Fisher 344 rat having an age between 9 and 11 weeks and a
weight between 200 and 300 grams. In accord with this
measure, the testing is performed on rats with a standard
deviation of 25% (relative) of the biocompatible material
and a population size of 10. In other words, when 10 of these
scaffolds are implanted into the Subcutaneous sites of rats,
on average at least 20 wt % of the scaffolds material
biodegrades within six weeks; and in at least 68% of rats at
least 15 wt % of the scaffold biodegrades; and in at least 90%
of rats at least 10 wt % of the scaffold degrades. Biodegrad
ing in most instances manifests itself as scaffold weight loss,

material remains for at least two weeks and does not

biodegrade within two weeks. That is, the concentrations of
glass formers are balanced such that at least about 50 wt %
of the biocompatible material remains for at least two weeks
after implantation in a Fisher 344 rat having an age between
9 and 11 weeks and a weight between 200 and 300 grams.
In accord with this measure, the testing is performed on rats
with a standard deviation of 25% (relative) of the biocom
patible material and a population size of 10. In other words,
when 10 of these scaffolds are implanted into the rats, on
average at least 50 wt % of the scaffolds material does not
biodegrade within two weeks; and in at least 68% of rats at
least 37.5 wt % of the scaffold does not biodegrade within

60

are “water soluble' are subject to relatively rapid solubility:
and materials which are “water insoluble' are either entirely
insoluble in water, or are at least only dissolvable with
difficulty. Generally speaking the scaffold materials are not
water insoluble and are not water soluble under this char
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acterization; rather, they are of intermediate water solubility.
In one embodiment the director element is incorporated
into aborate-based glass material containing the following,
approximately, with all percentages herein being by weight,
unless stated otherwise:
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to refer to the final composition as containing a given "% of

B2O3
Na2O
Li2O
KO
Rb2O

40 to 8O
O to 25
O to 25
O to 25
O to 25

CaO

2.5 to 50 (or 45)

MgO

O to 25

SO
BaO

O to 40
O to SO

Li2O + NaO + KO + Rb2O
MgO + SrO + BaO + CaO

O to 50 cumulative
O to 50 cumulative

P-Os
SiO,
Al2O3

O to 10
O to 18
O to 3

transition metal elements

O to 4
O to 10 cumulative.

the individual oxides, so that is done here. So from this

perspective, the compositions herein are on an equivalent

basis.

10

15

The concentrations of KO and MgO in certain of these
embodiments are each from about 1 to about 25 wt %. In

most embodiments, the one or more of LiO, NaO, KO.
and RbC) is present in a cumulative concentration between
about 1 and about 50 wt %, such as between about 5 and

about 20 wt %; and the one or more of MgO, SrO. BaO, and
CaO is present in a cumulative concentration between about
1 and about 50 wt %, such as between about 5 and about 40

wt %. Where Cu is the director element, this composition

vated and in fact hollow as interior borate material biode
25

further contains at least about 0.05 wt %, or at least about 0.1
wt %, such as between about 0.05 and about 5 wt %, for
30

electrons per atom, and includes, among others, Co and Ni.
In fact, certain of the director elements used in accordance
with this invention Such as Zn and Fe are transition metals.
So in formulations where the director element concentration

of these director elements is stated to be in a particular range

35

such as between about 0.1 and about 2.5 wt %, of course the

director element concentration is in that range regardless of
the fact that transition elements may be among the director
elements, and if Zn and Fe are present in an amount greater
than 2.5 wt %, they are not director elements.
In most embodiments the biocompatible material consists
only or essentially of components meeting these composi
tional requirements or other narrower descriptions herein.
But generally speaking, for some embodiments other mate
rials not meeting these descriptions may be incorporated into

biodegrades and is filled with soft tissue, including blood
vessels, bodily fluids, and the like. Accordingly, in vivo the
fibers after bioreaction have tubular and hollow aspects
which are filled with soft tissue, as the initially hollow
interior of the fiber is replaced with soft tissue including
blood vessels, bodily fluids, and the like. The borate mate
rials described herein also release boron in vivo as they react
with the bodily fluids.
In one preferred embodiment, the material contains
between about 50 and about 80 wt % B.O.; between about
5 and about 20 wt % alkali oxide component selected from
the group consisting of Li2O, NaO, K2O, Rb2O, and
combinations thereof, and between about 5 and about 40%

40
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the scaffolds.

It can therefore be appreciated that in addition to the
director element, the borate-based biocompatible materials
in certain embodiments include 40 to 80 wt % BO, or 50
to 80 wt % BO, or even the narrower BO ranges
described herein, in combination with 1 to 25 wt % Nao. 1
to 25% KO, 1 to 40 wt % CaO, 1 to 25 wt % MgO, and 1
to 10 wt % POs. Or the component materials may contain
40 to 80 wt % BO, 1 to 25 wt % LiO, and 5 to 40 wt %
CaO. Or they may contain 40 to 80 wt % BO, 1 to 25 wt
% NaO, and 1 to 40 wt % CaO. Or they may contain 40 to
80 wt % BO, 1 to 25 wt % NaO, and 1 to 40 wt % BaO.
Or they may contain 40 to 80 wt % BO, 1 to 25 wt % LiO,
and 1 to 25 wt % MgO. Or they may contain 40 to 80 wt %
BO, 1 to 25 wt % LiO, and 1 to 40 wt % BaC).
While the biocompatible materials hereinabove and here
inbelow are described as containing various oxides by
weight%, those skilled in the art understand that in the final
glass or glass/crystalline composition, the oxide compounds
are dissociated, and the specific oxides, e.g., B.O., SiO,
POs, etc. are not separately identifiable or even necessarily
separately present. Nonetheless, it is conventional in the art

grades. Upon reaction in vivo, interior segments of borate
based fibers become excavated as interior borate material

example between about 0.1 and about 2.5 wt % Cu.O. The
transition metal elements are those elements where the
d-band contains less than its maximum number of ten

The biocompatible materials of the invention containing
the director element in certain preferred versions are borate
based in that they contain between about 40 and about 80 wt
% BO, such as between about 50 and about 80 wt % B.O.
Borate-based materials have several important advantages
for biological use such as their ease of preparation, ability to
be made into glass particulates, microspheres or fibers at
relatively low temperatures without crystallization, their
angiogenicity and bacteriostaticity, and, particularly, their
biocompatibility. The borate-based materials disclosed
herein, compared to silicate-based materials, have signifi
cantly faster—e.g., 3 to 10 times—reaction rates, lower
melting temperatures, resistance to crystallization, and in
certain instances the absence of silica, which only slowly
degrades in the body. So while certain embodiments employ
up to about 18 wt % SiO in many other preferred embodi
ments herein, the materials are silica-free, containing less
than 0.1 wt % silica or even no silica. Upon reaction in vitro,
interior segments of the borate-based fibers become exca

50

alkaline earth component selected from the group consisting
of MgO, SrO. BaO, and combinations thereof. Lanthanides
are specifically and strictly excluded from certain preferred
embodiments. In some embodiments the biocompatible
material consists essentially of between about 50 and about
80 wt % B.O.; between about 5 and about 20 wt % alkali
oxide component selected from the group consisting of
LiO, NaO, KO, Rb O, and combinations thereof;
between about 5 and about 40 wt % alkaline earth compo
nent selected from the group consisting of MgO, SrO, BaO.
and combinations thereof, and between about 0.05 and 5 wt
% director element.

In certain embodiments of the invention, the biocompat
ible material is selected to include at least two of the alkali

oxides LiO, NaO, KO, and/or RbO in a cumulative
55

concentration of between about 5 and about 25 wt %, such
as between about 8 and 20 wt %. It has been discovered to
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be advantageous to include two or more such alkali com
pounds in order to reduce the tendency for crystallization,
which ultimately improves the workability and manufactur
ability of the glasses, which can be important to making
scaffolds. Using more than one type of alkali (i.e., mixed
alkali) can reduce the cost of a glass, modify its reaction rate
with bodily fluids, and provide additional elements benefi
cial to tissue growth and regeneration.
A further feature of certain embodiments is that the
cumulative concentration of the alkaline earth oxides from

the group consisting of MgO, SrO. BaO, CaO, and combi
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example, one or more of LiO, Na2O, KO, RbC), Cs-O, or

13
nations thereof is in the range of 1 to about 50 wt %, such
as in the range of 1 to 30 wt %, or even about 8 to 25 wt %.

a mixture thereof in a concentration of about 8 wt % to about

Certain of these embodiments contain two or more such

55 wt %, such as about 10 to about 52 wt %. These

alkaline earth oxides in a range of 1 to 45 wt % cumulatively,
such as in the range of 5 to 25 wt %. If SrO is present in a
concentration which yields a Sr concentration above 10 wt
%, it does not qualify as a director element in accordance

phosphate- and silicate-based glasses also contain a calcium
component, one of CaO, CaF, or mixtures thereof. For
example, many of these glasses contain from about 5 to
about 40 wt % of CaO or CaF, or mixtures thereof, such as
about 10 to about 30 wt % of CaO or CaF, or mixtures
thereof, or about 10 to about 15 wt % of CaO or CaF, or
mixtures thereof. Accordingly, one of these embodiments
contains about 20 to about 65 wt % POs, and one or more
of LiO, NaO, KO, Rb,O, Cs-O, or a mixture thereof in a
concentration of about 8 wt % to about 55 wt %, and a
calcium component of in a concentration of about 5 to about
40 wt % of CaO or CaF, and Cu in a concentration of about

with this invention.

These embodiments into which the director element may
be incorporated and which employ mixed alkali oxide
contents contain BOs from about 40 to about 80 wt %.
Certain of these embodiments consist essentially of BO

10

from about 40 to about 80 wt %, mixed alkali oxides selected

from the group consisting of LiO, NaO, KO, and RbC),
and one of MgO, SrO. BaO, or CaO, plus the Cu containing
compound. Other embodiments consist essentially of BO

15

65 wt % P.O.s, and one or more of LiO, NaO, KO, Rb O.
Cs-O, or a mixture thereof in a concentration of about 10 wt
% to about 52 wt %, a calcium component of CaO or CaF

from about 40 to about 80 wt %, two or more alkali oxides

selected from the group consisting of LiO, Na2O, K2O, and
Rb2O, and two or more alkaline earth oxides from the group
consisting of MgO, SrO. BaO, and CaO, plus the Cu
containing compound. For example, the first four composi
tions in the table in Example 1 consist essentially of BO

or mixtures thereof in a concentration of about 5 wt % to

about 40 wt % of CaO or CaF2 or mixtures thereof, and Cu
in a concentration of about 0.05 to about 5 wt %, such as

between about 0.1 and about 2.5 wt %. Another embodiment

from about 40 to about 80 wt %, two or more mixed alkali

oxides selected from the group consisting of Li2O, NaO.
KO, and RbC) in a cumulative wt % between 5 and 25%,
and two or more from among MgO, SrO. BaO, and CaO in

25

a cumulative wt % between 8 and 25%. Other embodiments

optionally include one or more of POs, SiO, Al-O. F. and
30
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and Cu in a concentration of about 0.05 to about 5 wt %,

such as between about 0.1 and about 2.5 wt %. Another

embodiment contains about 20 to about 60 wt % SiO, and
one or more of LiO, NaO, KO, Rb2O, Cs-O, or a mixture
thereof in a concentration of about 10 wt % to about 52 wit
%, a calcium component of CaO or CaFor mixtures thereof
in a concentration of about 5 wt % to about 40 wt % of CaO

or CaF2 or mixtures thereof, and Cu in a concentration of
about 0.05 to about 5 wt %, such as between about 0.1 and

about 2.5 wt %. Another embodiment contains about 20 to

8 to 25 wt %, and even two or more such oxides cumula

tively in this range
The invention also encompasses a biocompatible compo
sition for implantation into a mammal to facilitate vessel
growth in repair, regeneration, and/or proliferation of bodily
tissue, wherein the biocompatible material is phosphate
based or silicate-based and is at least partially dissolvable in
mammalian bodily fluids, and the director element is incor
porated into the biocompatible material in a concentration as
described above. In these embodiments, POs and/or SiO,
are glass formers and constitute about 20 to about 65 wt %
POs or about 20 to about 60 wt % SiO. These materials
also contain an alkali metal oxide component of for

%. Another of these embodiments contains about 20 to about

60 wt % SiO, and one or more of LiO, NaO, K2O, Rb2O,
Cs-O, or a mixture thereof in a concentration of about 8 wit
% to about 55 wt %, a calcium component of CaO in a
concentration of about 5 to about 40 wt % of CaO or CaF,

such as from about 5 to about 25 wt %, and even from about

8 to about 20 wt %; and even optionally two or more such
oxides cumulatively in this range. They also employ alkaline
earth oxides from group consisting of MgO, SrO, BaO, CaO.
and combinations thereof in the range of about 1 to about 50
wt %, such as in the range of 1 to 30 wt %, or even about

contains about 20 to about 65 wt % POs, and one or more
of LiO, NaO, KO, Rb,O, Cs-O, or a mixture thereof in a
concentration of about 8 wt % to about 55 wt %, a calcium
component of CaO or CaF2 or mixtures thereof in a con
centration of about 10 to about 30 wt % of CaO or CaF, or
mixtures thereof, and Cu in a concentration of about 0.05 to
about 5 wt %, such as between about 0.1 and about 2.5 wt

transition metal elements.

The invention includes incorporating director element
into biocompatible materials with an especially high BO
composition, namely, from about 60 to about 82 wt %, still
more preferably from about 70 to about 80 wt %. These
embodiments employ an alkali oxide selected from the
group consisting of LiO, NaO, K2O, Rb2O, and combi
nations thereof cumulatively from about 1 to about 50 wt %,

0.05 to about 5 wt %, such as between about 0.1 and about

2.5 wt %. Another embodiment contains about 20 to about
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about 60 wt % SiO, and one or more of LiO, NaO, KO.
Rb2O, CSO, or a mixture thereof in a concentration of about
8 wt % to about 55 wt %, a calcium component of CaO or
CaF, or mixtures thereof in a concentration of about 10 to
about 30 wt % of CaO or CaF2 or mixtures thereof, and Cu
in a concentration of about 0.05 to about 5 wt %, such as

50

between about 0.1 and about 2.5 wt %. In certain of these

embodiments, CaF2 is strictly avoided and the calcium
component is CaO.
Examples of silicate-based biocompatible material con
taining director elements in accordance with this invention
are as follows:

Glass SiO2 Na2O POs CaO CuO Fe0 CaF2 BO, ZnO MnO, MgO KO
A
B
C
D
E
F
G.

44.6
441
43.7
43.2
42.8
440
S.O.O

24.3
24.O
23.8
23.5
23.3
2SO
6.0

5.9
5.9
5.8
5.8
5.7

24.3
24.O
23.8
23.5
23.3
2O.O
19.0

1.O
2.0
3.0
4.0
S.O
O.2
O.2

1.O
1.O

2.2
3.0

O6
1.O

O.6
12.0

US 9,561,303 B2
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Examples of phosphate-based biocompatible glass con
taining director elements in accordance with this invention

16
contain the director element, or that the director element

are as follows:
Glass

ID
P-1
P-2
P-3
P-4
P-5
P-6
P-7

Na2O KO CaO MgO B.O. POs Li2O SrO CuO
3.8
9.2
7.8
7.8
6.6
1O.S
8.0

S.8
9.3
11.8
11.8
89
O.O
3.7

27.5
27.5
17.O
17.O
21.9
230
1.5

2.5
O.O.
76
76
O.O
O.O
O.O

O.O
O.O
O.O
O.O
41
4.O
1.8

6O.O
S3.5
SS.2,
SS.2,
58.O
611
78.1

O.O.
O.O.
O.O.
O.O.
O.O.
11
O.O

O.O.
O.O.
O.O.
O.O.
O.O.
O.O
6.7

O.4
O.S
O.6
O.6
O.S
O.3
O.2

These phosphate-based formulations demonstrate situa
tions where it is advantageous to include at least two of the
alkali oxides LiO, NaO, K2O, and/or Rb2O in a cumulative

10

such as fibers.
15

concentration of between about 5 and about 25 wt %, such
as between about 8 and 20 wt %. As noted above, it has been

discovered to be advantageous to include two or more Such
alkali compounds in order to reduce the tendency for crys
tallization, which ultimately improves the workability and
manufacturability of the glasses, which can be important to
making scaffolds. Using more than one type of alkali (i.e.,
mixed alkali) can reduce the cost of a glass, modify its
reaction rate with bodily fluids, and provide additional
elements beneficial to tissue growth and regeneration. In one
embodiment Na and K are incorporated into the glass and
upon dissolution the glass releases both of these necessary
elements to the host’s bodily fluids.
A further feature of these phosphate-based embodiments

different levels of porosity, for example between about 15
and about 30 vol%, or between about 30 and about 60 vol

25

30
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scaffolds. Because tissue repair is strongly influenced by the
flow of bodily fluids into the scaffold, it is preferred to have
a high level of interconnectivity of pores within the scaffold,
and a low level of closed pores. That is, it is important that
most pores be connected to other pores, and that there is a
director indirect path from most pores to the exterior surface
of the scaffold. In certain embodiments, at least about 80 vol

%, such as at least about 90%, of the pore volume of the
scaffold is directly or indirectly through other pores acces
sible from the scaffold exterior, and therefore accessible to
40

bodily fluids. The scaffold has interconnectivity of at least
about 75%, preferably at least about 85%, by which it is
meant that at least 75% or 85% by volume of the pores is
interconnected.
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one form, such as fibers, in combination with a minor

constituent of a second form from the foregoing options,
Such as microspheres.
There is also an option with this invention of employing
distinct component compositions to strategically impart cer
tain properties. For example, the composition in some
embodiments is “blended in that it employs 10 to 90 wt %
of components having one composition selected from the
above, and 10 to 90 wt % of components of a different
composition. Or even more than two Such types of compo
nents may be employed. That is, the material may contain at
least 10 wt % of components comprising a first component
material within the contemplated compositions and at least
10 wt % of components comprising a second component
material, wherein the first and second component materials
have compositions measurably distinct from each other. And
it is contemplated that only the first component material may

%, or between about 60 and about 90%, which are preferred
for different applications. Porosity depends on or is con
trolled by many factors such as fiber orientation, shape of
particles or microspheres, and the thermal treatment (time/
temperature) used to bond the elements together. Indepen
dent of this bulk porosity, interconnectivity is also important
in embodiments of the invention which are in the form of

25 wt %. Certain of these embodiments contain two or more

such alkaline earth oxides in a range of 1 to 45 wt %
cumulatively, such as in the range of 5 to 25 wt %.
The biocompatible materials of the invention are in the
form of solid fibers, hollow fibers, ribbons, solid spheres,
hollow spheres, particles, and combinations thereof. In an
especially preferred embodiment for many applications, the
composition is in the form of a scaffold body which includes
fibers, and in certain such embodiments it is a scaffold body
which consists essentially of components which are fibers.
The fibers have an aspect ratio of at least 2:1 length:
transverse dimension (e.g., diameter), and more typically at
least 5:1. Such as greater than 10:1. In certain embodiments
of the invention, the scaffold body components are primarily

In one embodiment the director element is incorporated
into the materials and a scaffold is formed to have a porosity
which is selected to provide fluid flow into the scaffold to
facilitate uptake of bodily fluids, while maintaining suffi
cient strength for handling and implantation. The porosity is
between about 15 vol % and about 90 vol%. There are

is that the cumulative concentration of the alkaline earth

oxides from the group consisting of MgO, SrO, BaO, CaO.
and combinations thereof is in the range of 1 to about 50 wt
%, such as in the range of 1 to 30 wt %, or even about 8 to

may be present in both materials in different amounts. This
permits the selection of, for example, faster reacting fibers in
combination with slower reacting fibers; or the selection of
Ca-containing fibers with Ca-free fibers. One can therefore
select standard composition components and combine them
with non-standard composition components to effectively
customize or dope the scaffold for the application presented,
or for the host’s particular needs. Alternatively, hollow
spheres containing a growth factor or drug for delivery to the
host can be incorporated with other structural components,
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The method of making the biocompatible materials is not
narrowly critical to the invention. By way of example, in
preparing the biocompatible materials, individual analytical
reagent grade components are weighed, mixed thoroughly,
and melted in a platinum crucible at temperatures between
1000 to about 1500° C., depending upon composition for
approximately one to four hrs. The melt is then quenched,
for example, on a steel or copper plate to form glass that can
be ground into particulates of a desired size. The particulates
can be spheroidized to form microspheres of a chosen
diameter. The material of certain preferred compositions
when in the form of a melt can easily be formed into fibers.
If fibers of the borate glass are made, they can either be
pulled by hand directly from the melt or pulled through
bushing by a rotating drum.
The components can be self-bonded to form three dimen
sional scaffolds by simply heating an assemblage of par
ticulates in a furnace and allowing the fibers/particles/
spheres to soften and bond to each other. After the allotted
time at temperature, the construct is removed from the
furnace and cooled to room temperature. Many prior bio
compatible glasses, such as 45S5, are difficult to self bond
due to crystallization of the glass. Therefore the self-bonding
ability of borate glasses is a distinct advantage over other
biocompatible materials currently in use.

US 9,561,303 B2
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In one embodiment the invention is a scaffold adapted for
soft tissue growth which is prepared from fibers which are
aligned so that a majority of the fibers are substantially
aligned in a parallel direction. The scaffold is prepared by
placing and orienting fibers in a unidirectional manner in a
mold. The fibers in the mold are heated to a temperature
where the fibers soften and bond together. In one preferred
embodiment, the fibers are self bonded in the sense that no

adhesive or other external bonding agent is used for bond
ing. An alternative embodiment employs a biocompatible
agent or adhesive to facilitate bonding, such that the fibers
are not self bonded, at least in part. Upon cooling, the
assemblage of bonded fibers is Sufficiently rigid and strong
that the assemblage can be removed from the mold and
handled. The scaffold is sufficiently rigid that it can be
implanted into a mammal where it facilitates the repair and
regeneration of hard tissue Such as bone (including cortical
and cancellous) or soft tissue such as muscle, cartilage, skin,
organ, or other hard or Soft tissue.
The orientation of the fibers in a lengthwise direction in
the self-bonded scaffold provides lengthwise channels (or
connected pores) among the fibers, which channels provide
for uptake into the scaffold of stem cells, growth factors,
medicines, proteins, red blood cells and other physiological
materials and components carried in bodily fluids. The fibers
are arranged to define channels within the scaffold which
facilitate fluid flow into and lengthwise within the scaffold
from one end to the other end. The orientation also provides
for channels in a transverse direction generally perpendicu
lar to the lengthwise direction of the oriented fibers, to
facilitate uptake of fluids from the outer surface of the
interior or core of the scaffold. These longitudinal and
transverse channels exert significant capillary forces on a
liquid which cause the liquid to be drawn into the scaffold.
This capillary action facilitates the distribution of these
fluids and components relatively uniformly throughout the

10
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other fibers in the scaffold. And each fiber is oriented

generally in the same direction, but each is not oriented in
exactly the same direction. Moreover, the scaffold itself in
certain embodiments is curved, bent, or otherwise not

25
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scaffold and enables fluids to flow from one end of the
scaffold to the other or to enter the scaffold from its surface

and draw the liquid inward to the center and ends of the
scaffold.

40

The invention in one embodiment employs fibers having
a diameter, prior to molding and softening, between about 20
and about 5000 microns, such as between about 50 and
about 5000 microns. In one embodiment the scaffold is

prepared from fibers having diameters between about 100

45

and about 450 microns, such as between about 100 and
about 300 microns. In an alternative embodiment, the scaf

fold is prepared from fibers having diameters up to about
3000 or 5000 microns (3 to 5 mm), which can be deemed
more akin to rods than fibers in some contexts, but for

50

purposes of the discussion of this invention fall within the
definition of “fibers.

In one aspect of the invention employing co-aligned
fibers, at least about 75 or 85% by volume of the fibers in the
scaffold are longitudinally co-aligned. In this regard the
fibers are co-aligned longitudinally, where “co-aligned lon
gitudinally and the like phrases (e.g., "in lengthwise co
alignment') as applied to a group of adjacent, bundled, or
joined fibers in this application means that the alignment of
each fiber in the group at any one place along at least about
75% of its length does not deviate more than about 25
degrees from parallel to the central axis of the scaffold. For
illustration, an example of co-alignment is the alignment of
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straight, in which cases the central axis of the scaffold to
which the alignment of the fibers is within 25 degrees of
parallel is also curved, bent, or otherwise not straight. In the
case of a curved scaffold, the fibers must be small enough in
diameter to be sufficiently flexible to take on a curved
configuration without breaking. In certain embodiments a
straight or curved scaffold is machined into a more complex
shape, in which instance the scaffold central axis refers to the
central axis as molded and prior to machining.
In order to allow capillary action and channel-forming,
the scaffold theoretically contains at least three fibers,
although the scaffold typically comprises dozens and even
hundreds of fibers. The fibers lie generally lengthwise of the
scaffold central axis A (i.e., lie generally in the direction of
the central axis) and are generally free of helical orientation
about the scaffold central axis. This arrangement applies to
at least about 75 vol % of the fibers and preferably to
substantially all of the fibers.
The aspect of this embodiment that the fibers are co
aligned longitudinally contemplates that the fibers are posi
tioned so that they have a similar alignment, which similar
alignment may be straight, bent, or curved. In most embodi
ments they are non-helical. In a separate and distinct aspect
of certain preferred embodiments, this common alignment is
limited to a generally straight alignment along at least about
75%, 85%, or 95% of the length of the fibers. In other words,
at least about 75%, 85%, or 95% of each fiber is generally
straight, i.e., at least about 75%, 85%, or 95% of the length
of each fiber has an alignment which is within 10 degrees of
a mean straight central axis for the fiber. So up to 5%, 15%,
or 25% of the length of each fiber may be curved, bent, or
otherwise deviate more than 10 degrees from straight in
relation to the overall fiber length, but the rest of each fiber
is generally straight in that it so deviates less than 10
degrees. In one preferred embodiment, Substantially the
entire length of each fiber is generally straight in that it
deviates less than 10 degrees from the fibers average central
axis. The “mean straight central axis is the imaginary
central axis for the fiber which is absolutely straight and is
an average of all axes along the fiber length.
The fibers in the scaffold of these embodiments are

selected to have characteristics suitable for the specific
application. In one embodiment, the fibers have a length

individual wires or filaments in a multistrand/filament cable.

In one preferred embodiment, each fiber in the group at any
one place along at least about 75% of its length does not
deviate more than about 15 degrees from parallel to the

18
central axis of the scaffold. In another preferred embodi
ment, each fiber in the group at any one place along at least
about 75% of its length does not deviate more than about 10
degrees from the central axis of the scaffold. So it is evident
that this co-alignment aspect does not require 100% precise
co-alignment of all fibers. The longitudinal co-alignment
aspect also allows for some minor deviation of specific
segments of individual fibers to an orientation outside these
25, 15, and 10 degree requirements. This is reflected in the
requirement that the longitudinal co-alignment is of each
fiber along at least 75% of its length, rather than necessarily
along its entire length. So up to about 25% of the length of
an individual fiber may be misaligned because, for example,
it was bent during the scaffold-making process or otherwise.
Each fiber in the scaffold is not absolutely straight, nor is it
lying along an absolutely straight line strictly parallel to all
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between about 2 mm and about 150 mm, such as between
about 2 and about 20 mm, between about 12 mm and about
100 mm, or between about 25 mm and about 75 mm. Each

fiber has a length which is at least about 10 times its

US 9,561,303 B2
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diameter. "Diameter as used herein refers to the fiber's

largest dimension transverse to its length, and it does not
imply that the fibers are perfectly circular in cross section.
Each fiber therefore has a fiber lengthwise dimension which
is at least about 10 times the fiber transverse dimension, e.g.,
diameter. In one embodiment, the fiber length is selected so
that all, substantially all, or at least about 85 vol% of the
individual fibers extend the entire length of the scaffold. The
fibers may be selected to have a pre-molding, pre-joining
length which corresponds to the length of the scaffold. Or in
most embodiments, the length of the fibers is longer than the
desired ultimate scaffold length, and the scaffold is cut to the
desired length after molding and joining. In an alternative
embodiment, the length of a Substantial portion (e.g., at least
40 vol%) or all of the fibers is significantly less than the
entire length of the scaffold.

10
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The scaffold in these embodiments is manufactured to

have a sufficiently high open and interconnected porosity
from end to end of the scaffold to facilitate capillary flow of
fluids such as bodily fluids and medicines and components
they carry through the length of the scaffold, as well as
generally transverse from outside walls of the scaffold into
the scaffold interior in directions generally transverse to the
longitudinal dimension of the fibers. And the scaffold is
manufactured so that the ultimate porosity is low enough
that the scaffold has the required strength for handling,
implantation, and service after implantation. If the porosity
is too high, the scaffold risks breakage in service, depending
on where it is implanted and the loads it encounters. In a
preferred embodiment, the porosity as measured in Volume
is between about 10% and about 35%, for example between
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1 wt %, crystallization when the material is heated to 800°
C. at an average heating rate of 20° C./min, held at that
temperature for 10 minutes, then cooled to room tempera
ture by exposure to STP conditions of room temperature and
atmospheric pressure. More preferably, the glass will con
tain less than 5 wt % crystallization, even more preferably
less than 1 wt % crystallization, after being heated to 575°
C. with a ramp rate of 20° C./min, and held at that tem
perature for 20 minutes, then cooled to room temperature by
exposure to STP conditions. The fibers used in many
embodiments of the invention, consistent with the foregoing
description, are at least 99 wt % an amorphous or non
crystalline solid, for example made by fusing a mixture of
oxides such as one or more of SiO, BO, POs (known as
glass forming oxides) with basic oxides such as the alkali
and alkaline earth oxides, along with the director element. In
an alternative embodiment, the fibers include glass ceramics
fibers that contain both glassy and crystalline regions which
in many respects function in the same manner as a fiber that
is completely (100%) non-crystalline. It is acceptable in
Some applications if the glass fiber crystallizes during the
bonding step. Some of the fibers may alternatively be
pre-reacted prior to bonding for the purpose of forming a
thin surface layer of different chemical composition, for
example, a deakalized layer, or a thin layer of hydroxyapa
tite or other biologically useful Substance (tricalcium phos
phate, octacalcium phosphate, dihydrogen calcium phos
phate).
Example 1

Several glasses were prepared with the following com
positions:

about 10% and about 30%, or between about 10% and about
Glass

B2O

SiO2 Na2O CaO KO MgO POs CuO SrO ZnO Fe2O.

13-93B3
B3 Cu-3
B3-CS
B3-CSZ,
B3-CSZF
93-CSZF

53.00
52.79
51.73
S1.2O
SO.88

6.OO 20.OO 12.OO SOO
S.98. 19.92 11.9S 4.98
5.86 19.52 11.71 4.88
5.8O 1932 11.59 4.83
576. 19.2O 1152 4.8O
SO.88 5.76 19.2O 1152 4.80

25%. The porosity is controllable mainly by controlling the
degree of softening of the fibers during thermal treatment, in
that highly softened fibers fuse together more completely to
a structure with lower porosity. The degree of softening and
fusing is controlled by controlling the bonding temperature
and time. Porosity is also affected by the fiber diameter and
by the range in fiber diameter within a given scaffold.
Porosity tends to increase with an increasing range in fiber
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diameter.

The biocompatible material may be glassy, glass ceramic,
or ceramic in nature. However the glassy state is preferred
in this invention because, generally speaking, glassy mate
rials are easier to form into different shapes, bond at lower
temperatures and are more chemically homogeneous than
their crystalline or partially crystalline counterparts of the
same composition. It is therefore preferable that the bio
compatible material is Substantially glass in that less than
about 5 wt %, more preferable less than 1 wt %, of the
component material is crystalline material. More particu
larly, it is preferable that there is less than 5 wt %, preferably
less than 1 wt %, crystallization when the material is heated
to a temperature needed to bond the individual glass par
ticles together. By way of example, in one embodiment it is
preferable that there is less than 5 wt %, preferably less than

4.OO
3.98
3.90
386
384
3.84

0.40
O.40
O.40
O.40
0.40

2.00
2.OO
2.OO
2.OO

1.OO
100
100

0.40
0.40

Scaffolds were prepared from glasses B3 Cu-3, B3 CS, B3
CSZ, and B3 CSZF. Continuous fibers of these glasses were
broken into lengths of two to three millimeters (FIG. 1A),
placed in a ceramic mold in a random fashion, and heated to
575°C. for 45 minutes to bond the fibers into rigid scaffolds
as shown in FIG. 1B. After heating, the molds were removed
from the furnace, and cooled to room temperature. Once at
room temperature, the scaffolds were removed from the
molds and ready for use. An example of a scaffold is shown
in FIG. 1C. The scaffolds were 2 mm thick and 7 mm in

55

diameter, and weighed ~70 mg.
Example 2
Five scaffolds of each glass were seeded with mesenchy
mal stem cells, and five were unseeded. The scaffolds were
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implanted into one of four possible locations in the Subcu
taneous tissue of Fisher 344 rats having an age between 9
and 11 weeks and a weight between 200 and 300 grams as
shown in FIG. 2 for six weeks. A scaffold was placed above
each of the front shoulders and above both hind legs as
indicated. The cut made in the skin shown by the horizontal
lines was approximately 20 mm wide and the pocket made
under the skin (dotted line) is about 20 mm long. The dashed

US 9,561,303 B2
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line represents the spine as a reference. Representative
images of the appearance of each scaffold upon extraction

22
reacted but not hollow as were the B3 Cu-3 and B3 CS

are shown in FIG. 3. Soft tissue had infiltrated into each

scaffold and significant vascular growth had occurred.
Example 3
A scaffold of each type was x-rayed after removal from
the rats to identify any crystalline phases formed while in the
animal. The XRD patterns for each scaffold are shown in 10
FIG. 4. The B3 Cu-3 and B3 CS glasses reacted with bodily
fluids to form hydroxyapatite (Caio (PO4)(OH)), although
the hydroxyapatite was not necessarily stoichiometric. The
XRD peaks are smaller in the pattern for the Cu-3 glass than
those in the pattern for the 13-93B3 glass because the 15
addition of copper slowed the HA formation kinetics, and
since the crystals may still be in the process of fully
crystallizing, the crystals are Smaller and therefore less
detectable, or possibly a combination. Either way, it is
significant that the Cu-3 glass formed a material that when 20
X-rayed had HA peaks of lower intensity than those for the
13-93B3 glass. Raman spectroscopy of reacted B3 Cu-3 and
B3 CS fibers as discussed further below indicated that a

carbonated form of hydroxyapatite known as HCA was
present. The B3 CSZ glass reacted to form what appeared to 25
be a multi-phase mixture of hydroxyapatite and calcium
carbonate (calcite). The XRD patterns of the reacted B3
CSZF scaffolds contained larger peaks for calcite only. This
is believed to be the first documented instance known to the

inventors where any type of a calcium-containing glass 30
implanted in an animal has reacted to form calcite or any
other material other than HA/HCA.

Example 4
35

Cross sections of the various scaffolds after removal were

prepared and examined. FIG. 5 is an SEMBSE image of the
B3 Cu-3 scaffold (borate glass doped with Cu) after six
weeks in Subcutaneous tissue. All of the as-made borate

glass fibers have reacted with the bodily fluids to form 40
hydroxyapatite, see FIG. 4, and as a consequence, most of
the fibers have become partially excavated. The hollowing
effect is caused by the glass containing too little calcium to
form enough hydroxyapatite upon reaction with the phos
phate present in the bodily fluids to form a solid fiber. A 45
similar reaction product, hydroxyapatite, is present in the
SEMBSE of the borate B3 CS glass (doped with Cuplus Sr)
in FIG. 6 and the reacted fibers are again mostly hollow. A
reacted fiber from the B3 CS scaffold was chosen for

compositional analysis, and is shown in FIG. 7. The chemical composition was measured at the three numbered spots
across the fiber in FIG. 7, and SEMEDS spectra generated
for analysis. The Ca/P molar ratio of the material at the three
numbered spots is shown in the figure. Except for trace
amounts of Na, Mg, and K; Ca and P were the major
components at each spot and the similarity in the peak height
for each in the spectra revealed that the chemical composi
tion of the reacted fiber is similar from the center (point 3)
to the outer surface (point 1). The XRD data in FIG. 4
indicate that the initially glass fibers had converted to HA.
The SEMBSE image of a scaffold made from B3 CSZ
fibers (doped with Cu, Sr., and Zn), is shown in FIG. 8. Some
of the larger diameter fibers in the lower left side of the
image, which have a white material in the center have not
fully reacted with the bodily fluids. The white core is
composed of the unreacted B3 CSZ glass. The fibers at the
outer edge of the scaffold (right center and side) are fully
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fibers. A relatively small region of a calcium containing
material is present at the center of the B3 CSZ fibers. This
is better illustrated by the fiber in FIG.9, where three distinct
layers of material are visible. The composition at the four
numbered spots across the fiber was measured by SEMEDS.
At spot 1 (center) only calcium and oxygen were detected
along with trace amounts of Mg, and K. Carbon may have
been present, but is undetectable by SEMEDS, so this
material is consistent with being CaCO as found by XRD,
see FIG. 4. The SEMEDS spectra at spots 2 and 3 contained
peaks for both calcium and phosphorus with an intensity
ratio similar to that of hydroxyapatite. Spot 4 (at the outer
edge) contained both calcium and phosphorus and had the
highest signal among spots 2, 3, and 4. The SEMEDS and
XRD results indicate that a relatively dense layer of HA at
the outer Surface (spot 4) surrounds a more porous and
layered hydroxyapatite-like material at spots 3 and 2, and the
white, calcium rich, material at the core, spot 1, is most
likely calcium carbonate (calcite).
The SEMBSE image in FIG. 10 of the B3 CSZF scaffold,
made from fibers doped with Cu, Sr., Zn and Fe shows a
cross section of reacted fibers with a hydroxyapatite outer
layer and a calcium-rich core (lighter material) similar to
that shown for the B3 CSZ scaffold in FIG.8. The image in
FIG. 10 however shows there is significantly more calcium
present within the reacted fibers than in FIG. 8. The larger
amounts of calcium present in the B3 CSZF scaffold are
evident both visually in the SEM images in FIGS. 8 and 10
and by the height (size) of the peaks in the XRD patterns in
FIG. 4 which provide a positive identification that the
material is calcium carbonate, calcite. Verification that the
calcium-rich core in the B3 CSZF glass was calcite and free
of phosphate is provided by the SEM phase map for the
reacted B3 CSZF fiber, shown in FIG. 11. Calcium is present
throughout the fiber, in what is believed to be hydroxyapa
tite-like material and presumably calcium carbonate. How
ever, the largest concentration of calcium is at the core as
indicated by the bright spot in the upper left of FIG. 11.
There are only low levels of Mg, Sr., and K in the fiber
indicating that the glass has significantly reacted and most of
the elements have been released to the bodily fluids. Phos
phorus is present in the outer portions of the fiber but there
is a distinct area devoid of phosphorus in the center of the
fiber at the same area of highest calcium concentration,
which means there is no calcium phosphate present. SEM
EDS at four spots across the same fiber in FIG. 12 show a
similar reaction product as that present in the B3 CSZ fibers.
There is a thin outer layer (1-2 micron) of dense hydroxy
apatite (spot 4), a region of porous and layered hydroxy
apatite (spots 2 and 3), and a calcium rich core (spot 1) as
indicated by the relative intensity of the SEMEDS peaks.
The fiber reacted with bodily fluids and formed a distinctly
different material at the center (white). The Ca/P molar ratio
was measured with SEMEDS at the four numbered spots
indicated. As shown in FIG. 13, at higher magnification, the
reacted calcium-rich core (white center) had a similar lay
ered structure as that of the Surrounding hydroxyapatite,
which is formed as the glass reacts with bodily fluids. The
reaction of the borate glass fibers with the bodily fluids starts
at the external surface of the fiber and proceeds inward.
Example 5
To determine the role the minor director elements played
in the conversion reaction of the scaffolds, X-ray fluores
cence (XRF) was used to measure the composition of the
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as-made glass and the scaffolds reacted in vivo. The as-made
glass was measured to verify the presence of the minor
elements in the as-made glass, and to ensure the relative
concentrations of the minor elements were similar. The XRF

patterns for the minor elements of interest (Cu, Sr., Zn, and
Fe) for the fourglasses are shown in FIGS. 14A and 14B. All
four minor elements (Cu, Sr., Zn, and Fe) were present in the
as-made glasses (prior to implantation). The concentrations
of Cu were similar in all four of the as-made glasses as
expected, and the Zn concentration was essentially identical
in the two glasses to which it was added. The arrow in 14A
indicates a peak associated with the polymer mounting
material. A scaffold of each type seeded with mesenchymal
stem cells was analyzed to determine if the minor elements
(Cu, Sr., Zn and Fe) were detectable in the scaffold of soft
tissue after the in vivo reaction. The XRF patterns shown in
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FIGS. 15A and 15B are for scaffolds after six weeks in vivo,
and all four minor elements were detected in either the

reacted fibers or the new soft tissue. The Sr was weakly
detectable in the HA layers from the SEMEDS phase map in
FIG. 11; but the other minor elements (Cu, Zn,Fe) were of
too low concentration to determine if they were present in
the HA layer by SEMEDS. The arrow in 15A indicates a
peak associated with the polymer mounting material. The
XRF data in FIGS. 15A and 15B proves that at least some
of the minor elements were present in the reacted scaffold or
soft tissue adjacent to the fibers and not completely removed
by bodily fluids, which may explain why the fibers reacted
differently and calcium carbonate instead of HA was formed
in the B3 CSZ and B3 CSZF fibers.

would be free to bond with the silica to form a calcium

25

the hollow nature of the B3 Cu-3 and B3 CS fiber versus the
35
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A silicate based bioactive glass 13-93 was modified
similarly to that of 93B3 glass by adding small amounts of
Cu, Sr., Zn, and Fe according to the composition of 93-CSZF

the reacted fiber. The peaks associated with HA (431 cm
(PO, v2),965 cm (PO, v1), 1065 to 1070 cm (CO,
v1) and 1076 cm PO, v3) are denoted by dashed lines.
of FIG. 17.
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of a calcium rich core.

With additional compositional modifications, it should be
possible to completely block the formation of hydroxyapa
tite and form other calcium containing compounds (phos
phates, carbonates, hydrates, fluorides, etc.). Other combi
nations of minor elements may make it possible to form
compounds other than hydroxyapatite or calcium carbonate,
and make new multicomponent reaction products similar to
those described above. Mixing fibers of different composi
tions that form different reaction products as a blended
scaffold offers a way to make an entirely new family of
degradable materials that are biocompatible. These reaction
products are potentially useful in drug delivery or bone or
other soft tissue regeneration.
Example 6

Micro Raman analysis was performed on glasses of the
invention and glasses not of the invention to investigate
what compounds are formed in vivo.
A reacted 13-93B3 fiber of the composition described in
Example 1 (reacted four weeks in vivo) was analyzed by
micro raman at four locations, and the micro-raman spectra
for the four spots are shown in FIG. 17. Spot one is located
at the outer edge of the fiber and spot four at the center of
The solid lines indicate peaks due to the PMMA mounting
medium as demonstrated by the spectrum shown at the top

environment. The combination of minor elements with those

already present in the glass caused a change in the bonding
between the calcium and phosphorus which made a more
porous structure of hydroxyapatite followed by the deposit

silicate compound Such as Ca2SiO4. The formation of a
material other than HA in a bioactive silicate glass is
important because this means that the addition of minor
elements can be used in either silicate or borate glasses to
control or alter the reaction products that form when in
contact with bodily fluids or simulated bodily fluids and
different materials having desired properties can be made on
demand by this method of adding minor elements.
Example 7
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The contrast in color, or shading, of the SEMBSE images
between the B3 CS fiber and the B3 CSZF fiber along with
partially filled B3 CSZ and B3 CSZF fibers, with a calcium
rich core, points to a change in how the glasses react with the
bodily fluids and how calcium is potentially blocked from
reacting with the phosphate in the bodily fluids. The hollow
core of a reacted fiber or particle has been previously
described as what occurs in a glass which does not contain
enough calcium to form a fully dense structure composed of
HA. The B3 CS and B3 CSZF glasses had an almost
identical amount of calcium present and formed completely
different structures when they reacted in vivo in an identical

24
in the foregoing table. The glass was melted, plate quenched,
and crushed to a particle size range of 150 to 300 microns.
The particles were immersed in simulated bodily fluid for up
to 2 weeks at 37° C. and x-rayed for phase identification.
After 1 week in simulated bodily fluids, relatively broad
XRD peaks were present as shown by the bottom pattern in
FIG. 16, but no crystalline phases could be identified. In the
XRD pattern at 2 weeks (middle pattern in FIG. 16) Small,
barely detectable XRD peaks corresponding to HA (black
arrows) were present when compared to the top pattern
above which is for a bioactive borate glass reacted in vivo.
The large peaks at ~24 and 31 degrees 20 are not associated
with HA, but match well with CaSiO. There are several
other smaller peaks that match the standard XRD pattern for
CaSiO, and those peaks are indicated by the arrows in FIG.
16. Assuming the four minor elements in the glass prevent
the formation of calcium with phosphate to form a HA type
phase as in the borate glasses described earlier, the calcium
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Spots three and four located near the center of the reacted
13-93B3 fiber have the highest intensities for the phosphate
and carbonate peaks of the four spots analyzed, indicating
there may be a difference in the amount of each species
distributed throughout the reacted layers. The difference in
the measured amount of phosphate and carbonate measured
could also be due to density differences of the reacted fiber,
especially at the center with the layered microstructure. The
difference in the phosphate and carbonate concentration may
also indicate that the fiber is not completely converted. The

presence of a carbonate peak at 1065 to 1070 cm (CO’

V 1) indicates that the reacted fibers are carbonated, similar
to natural bone. The significance of this analysis is the
presence of hydroxyapatite and the absence of calcite in this
prior art glass containing borate as the primary glass former,
and also containing Na2O, CaO, K2O, MgO, and POs.
Micro Raman analysis of a Cu-3 fiber (Example 1) after
six weeks in vivo was performed at seven spots across the
cross section of a reacted fiber from its outer edge to its
center. See FIG. 18. The majority of the peaks in the Raman
spectra are due to the PMMA in which the scaffold is
mounted. The peaks important for identifying HA are

located at 431 cm (PO, v2), 965 cm (PO. v1), 1065
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As noted above, calcium-containing implantable bioac
tive glasses form hydroxyapatite upon reaction with bodily
fluids. In accordance with this invention, the glass compo

cm and 1070 cm (CO, v1), and 1078 cm (PO, v3).

The intensity of the HA peaks in spectra one to five are
almost identical indicating no significant change in the

material from the outer edge to the center. The PO, V2 and
PO, v3 peaks in spectra six are noticeably lower than the

sition is formulated to include the one or more director

15

elements so as to produce calcium compounds other than
hydroxyapatite. In some embodiments, these other calcium
compounds are formed entirely instead of hydroxyapatite. In
other embodiments, a mixture of hydroxyapatite and one or
more other calcium-based compounds is formed. In one
preferred embodiment of the invention, the implantable
glass composition is formulated to promote the formation of
calcite upon reaction with bodily fluids in vivo. Without
being bound to a particular theory, it appears the ionic radius
of a particular element has an impact on its efficacy as a

25

ments in accordance with this invention. In particular, it is
believed that an element with a relatively smaller ionic
radius Such as less than about 1 angstrom, or on the order of
0.8 angstroms or less, provides moderate to severe inhibition
of hydroxyapatite formation, and biases the system toward
calcite formation. FIG. 24 is a schematic graph showing
relative inhibition of hydroxyapatite in the presence of six
coordinated ions in aqueous environments.
Calcite is a polymorph of calcium carbonate that can be

5

corresponding peaks in spectra one to five. There was also

an increase in the intensity of the PMMA peak at 600 cm
center. The presence of CO, peaks are the first evidence

in spectra six indicating a higher porosity of the fiber at its
that the HA is carbonated similar to natural bone.

10

FIG. 19 shows micro Raman spectra of a CS fiber
(Example 1) after six weeks in vivo at five spots across the
fiber from its outer edge to its center. The only peaks

associated with HA are located at 428 cm (PO, V2) and
1070 cm (CO, v1), and 1078 cm (PO, v3). The 965
cm (PO, V1) peak for HA was not seen in any of the

the broad peak at 1065-1080 which encompasses 1065 and
spectra in FIG. 19.
FIG. 20 shows the ten spots analyzed by micro Raman
spectroscopy of a CSZ fiber (Example 1) after six weeks in
vivo from its outer edge to its center. The first five spectra
in FIG. 21 are from the outer edge to up to the interface
between the porous calcium phosphate and the calcium rich
center. No peaks associated with HA are present in the micro
Raman spectra for spots one to five. The spectra for the

found in nature in both seashells and coral. Calcite has been

calcium rich center in FIG.22 contain two peaks at 711 cm
and 1085 cm in spectra 6 to 10 and these peaks are
associated with calcium carbonate in the form of calcite.

FIG. 23 shows the six spots analyzed by micro Raman
spectroscopy for a CSZF fiber (Example 1) after six weeks
in vivo, from its outer edge to its center. No peaks associated
with HA were present in any spots analyzed. The peaks at
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711 cm and 1085 cm, attributable to calcite, were present

once inside the calcium rich center at spots four to six.
In summary, analysis of the reacted fibers showed that the
majority of un-doped fibers were fully converted to
hydroxyapatite after four weeks. The addition of the minor
elements affected the conversion of the bioactive glass
scaffolds to hydroxyapatite. The scaffold containing copper
converted to HA, but a slower rate than the base glass
without copper. The combination of copper and strontium
significantly retarded the reaction of the phosphate in the
bodily fluids with the calcium released from the borate glass
as determined by micro Raman measurements, but a highly
porous HA had formed instead according to XRD. The
addition of Zinc to the copper and strontium doped borate
glass effectively stopped the formation of calcium phosphate
(HA) toward the center of the fibers and formed calcium
carbonate in the form of calcite formed instead. When iron
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As various changes could be made in the above compo
sitions and methods without departing from the scope of the
invention, it is intended that all matter contained in the

above description and shown in the accompanying drawings
shall be interpreted as illustrative and not in a limiting sense.
50

The invention claimed is:

1. A biocompatible composition for tissue repair or regen
eration in mammals comprising:
40 to 80 wt % B.O.;
55

2.5 to 50 wt % CaO;

one or more of MgO, SrO, and combinations thereof in a

vivo.

cumulative concentration of 5 to 40 wt %;

The foregoing data show a progressive change in the
reaction of borate glasses with the bodily fluids of a rat. With
Fe, to a borate glass, the formation of HA ceases and
eventually only calcium carbonate is formed. The elements
that had the largest effect on the conversion of the glass to
HA were zinc and iron. The XRD first peaks for calcite
appeared in the CSZ (Ca,Sr., Zn) scaffold, and when a small
amount of Fe was added to that composition, HA could not
be detected by XRD, and only calcite was detectable.

“the' and “said are intended to mean that there are one or

elements.
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fibers continued to increase. This is believed to be the first

the addition of the minor elements, such as Cu, Sr., Zn, and

used as a degradable scaffold material and has been shown
to promote bone marrow induced osteogenesis better than a
comparable hydroxyapatite scaffold. Calcite has been
reported to remodel at a faster rate than natural or synthetic
HA and tricalcium phosphate through in vitro osteoclast
excavation experiments. Bone cement filled with calcite
powder has also been made for biomedical use. Accordingly,
the discovery herein of the ability to form calcite in vivo
with implantable glass compositions, and to reduce, mini
mize, and/or eliminate HA formation, presents a significant
advancement in treatment opportunities.
When introducing elements of the present invention or the
preferred embodiments(s) thereof, the articles “a”, “an',
more of the elements. The terms “comprising”, “including
and “having are intended to be inclusive and mean that
there may be additional elements other than the listed

was added to a glass doped with copper, strontium, and Zinc
the formation of calcium phosphate (HA) was decreased
even further as the calcite present at the center of the reacted
time calcium containing bioactive glasses were documented
to transform to materials other than calcium phosphates in

director element alone or in combination with other ele

one or more of LiO, NaO, KO, Rb2O and combinations
thereof;
60

one or more director elements selected from the group
consisting of Cu, Zn, Fe, Mn, Ba, Co., S. V. and/or Y in
a cumulative concentration between 0.05 and 5 wt % to

65

promote in Vivo calcium compound formation of cal
cium carbonate or other calcium-containing materials
other than hydroxyapatite;
wherein upon direct application of the biocompatible
composition to a mammalian host, calcium carbonate
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or other calcium-containing materials other than
1 to 25 wt % MgO
hydroxyapatite form upon bioreaction of the composi
1 to 10 wt % POs
O.1 to 2.5 wt % CuO.
tion with bodily fluids;
wherein the composition is in a form of one or more of
11. The biocompatible composition of claim 1 compris
fibers, hollow fibers, tubes, ribbons, solid spheres, 5 ing, approximately:
hollow spheres, particles, bonded particles, and com
40 to 80 wt % BO,
binations thereof assembled in a scaffold which has a
1 to 25 wt % NaO
porosity of between about 15 and about 90 vol% with
1 to 25% KO
at least about 75 vol% of pores being interconnected 10 5 to 40 wit 9% CaO
and Suitable for application to a mammalian host Such
1 to 25 wt % MgO
that it is exposed to the mammalian host’s bodily fluids
1 to 10 wt % POs
for tissue repair or regeneration in mammals; and
O.1 to 2.5 wt % CuO
wherein the composition is not water soluble.
O.1 to 2.5 wt % ZnO.
2. The biocompatible composition of claim 1 wherein said 15 12. The biocompatible composition of claim 1 compris
calcium carbonate or other calcium-containing materials ing, approximately:
other than hydroxyapatite that forms upon bioreaction of the
40 to 80 wt % BO,
composition with bodily fluids comprises calcite; and
1 to 25 wt % NaO
wherein hydroxyapatite also forms upon bioreaction of
the composition with bodily fluids.

2O

3. The biocompatible composition of claim 1 wherein
hydroxyapatite does not form upon bioreaction of the com
position with bodily fluids.
4. The biocompatible composition of claim 3 wherein the
director element is selected from the group consisting of Cu, 25
Zn, Fe, Mn, Ba, Co, and/or S.

5. The biocompatible composition of claim 3 wherein the
director element is selected from the group consisting of Cu,
Mn, Ba, Co, and/or S.

6. The biocompatible composition of claim 3 wherein the
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director element is Zn and/or Fe.

7. The biocompatible composition of claim 1 comprising,
approximately:
40 to 80 wt % BO
1 to 25 wt % NaO
1 to 25% KO

35

5 to 40 wit 9% CaO

1 to 25 wt % MgO
1 to 10 wt % POs
said one or more director elements;
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said one or more of LiO, Rb2O, SiO, Al-O, and F.
8. The biocompatible composition of claim 1 consisting of
approximately:
40 to 80 wt % BO
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1 to 25 wt % NaO
1 to 25% KO
1 to 25 wt % MgO

one or more of LiO, Rb2O, SiO, Al-O, and F.
9. The biocompatible composition of claim 1 comprising,
approximately:

1 to 25 wt % MgO
1 to 10 wt % POs
O.1 to 2.5 wt % CuO
O.1 to 2.5 wt % ZnO

0.1 to 2.5 wt % Fe...O.
wherein the one or more director elements is supplied by
said CuO, ZnO, and/or FeO.
13. A biocompatible composition for tissue repair or
regeneration in mammals comprising, approximately:
40 to 80 wt % BO,
1 to 25 wt % NaO
1 to 25% KO
5 to 40 wit 9% CaO

1 to 25 wt % MgO
1 to 10 wt % P.O.
one or more director elements selected from the group
consisting of Cu, Zn, Fe, Mn, Ba, Co., S. V. and/or Y in
a cumulative concentration between 0.05 and 5 wt % to

promote in Vivo calcium compound formation of cal
cium carbonate or other calcium-containing materials
other than hydroxyapatite;
optionally one or more of LiO, Rb2O, SiO, Al-O, and
F;

wherein the composition is in the form of a scaffold of
glass fibers;
wherein the scaffold has a porosity of between about 15

5 to 40 wit 9% CaO

1 to 10 wt % POs
and said one or more director elements,

1 to 25% KO

5 to 40 wit 9% CaO

and about 90 vol % with at least about 75 vol% of
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pores being interconnected;
wherein the glass fibers have lengths between about 2 and
about 150 mm and a length:diameter aspect ratio of at
least 5:1;

the composition is not water soluble.
40 to 80 wt % BO
55 wherein
14.
The
biocompatible composition of claim 3 wherein
1 to 25 wt % NaO
the composition comprises from 10 to 90 wt % of compo
1 to 25% KO
nents having one composition and from 10 to 90 wt % of
12 to 24 wt % CaO
components of a different composition.
1 to 25 wt % MgO
1 to 10 wt % POs
60 15. The biocompatible composition of claim 3 wherein
the composition is in the form of fibers and spheres.
O.1 to 2.5 wt % CuO.
16. The biocompatible composition of claim 1 wherein
10. The biocompatible composition of claim 1 compris
the one or more director elements are Zn and Fe.
ing, approximately:
17. The biocompatible composition of claim 1 wherein
40 to 80 wt % BO
1 to 25 wt % NaO

1 to 25% KO
5 to 40 wit 9% CaO

65 the one or more director elements is Zn.

18. The biocompatible composition of claim 1 wherein

the one or more director elements is Fe.
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19. The composition of claim 1 comprising fibers having
a diameter between 20 and 5000 microns.

20. The composition of claim 1 comprising fibers having
a diameter between 100 and 300 microns.

21. The composition of claim 1 comprising particles 5
having a particle size in the range of 150 to 300 microns.
k

k

k

k

k
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